Neonatal Anaphylaxis & Severe Drug Reactions: Emergency Management Protocol for NICU

Neonatal Anaphylaxis and Severe Drug Reactions: An Uncommon but Critical Emergency

Anaphylaxis and severe adverse drug reactions in neonates are rare but potentially fatal events that demand immediate recognition and protocolized management. The neonatal immune system is immature, with limited IgE antibody production, making classic anaphylaxis less common than in older children and adults. However, anaphylactoid reactions (direct mast cell degranulation without IgE mediation), transfusion reactions, and severe drug hypersensitivity reactions are well-documented in NICU settings. With the increasing complexity of NICU pharmacotherapy, including multiple antibiotics, blood products, and contrast agents, every NICU team must be prepared to manage these emergencies.

Types of Severe Drug Reactions in Neonates

Type	Mechanism	Common Triggers	Onset
True anaphylaxis	IgE-mediated mast cell and basophil degranulation	Penicillins, cephalosporins, latex, blood products	Minutes to 1 hour
Anaphylactoid reaction	Direct mast cell degranulation (non-IgE)	Vancomycin (Red Man), opioids, contrast dye, blood products	Minutes
Transfusion reaction (acute hemolytic)	Antibody-mediated RBC destruction	ABO-incompatible blood transfusion	Minutes to hours
Transfusion-related acute lung injury (TRALI)	Donor antibodies activating recipient neutrophils	FFP, platelets, RBC transfusion	1-6 hours
Serum sickness-like reaction	Immune complex deposition	Antibiotics (cefaclor, penicillins)	7-14 days
Stevens-Johnson Syndrome / TEN	T-cell mediated cytotoxicity	Phenobarbital, phenytoin, antibiotics	7-21 days

Clinical Recognition of Anaphylaxis in Neonates

Neonatal anaphylaxis is challenging to diagnose because classic symptoms like urticaria, angioedema, and vocal distress may be subtle or absent. Key clinical features include:

• Cardiovascular: Sudden hypotension, tachycardia (or bradycardia in severe cases), poor perfusion, cardiovascular collapse
• Respiratory: Acute bronchospasm, stridor, increased ventilator pressures (if intubated), desaturation, respiratory arrest
• Cutaneous: Erythema, urticaria (wheals), flushing (may be difficult to appreciate in dark-skinned neonates), periorbital or facial edema
• Gastrointestinal: Abdominal distension, vomiting, bloody stools (non-specific)
• Neurological: Irritability, lethargy, seizures (from hypoperfusion)

Diagnostic Clue: The temporal relationship between drug or blood product administration and the onset of symptoms is the most important diagnostic feature. A sudden deterioration within minutes of starting a new medication or transfusion should immediately raise suspicion for an adverse reaction until proven otherwise.

Emergency Management Protocol

Immediate Actions (First 5 Minutes)

1. Stop the offending agent immediately: Discontinue the drug infusion or blood product transfusion
2. Call for help: Activate the NICU emergency team
3. Administer epinephrine IM: 0.01 mg/kg (0.1 mL/kg of 1:10,000 solution) into the anterolateral thigh
4. Position: Lay flat; elevate lower extremities if possible
5. Ensure airway: Assess airway patency; intubate if signs of upper airway compromise
6. Supplemental oxygen: FiO2 1.0 via mask or ventilator
7. IV access: Ensure at least one functioning IV line; establish second access if needed

Secondary Actions (5-30 Minutes)

Drug	Dose	Route	Purpose
Epinephrine (repeat)	0.01 mg/kg	IM every 5-15 min as needed	Primary treatment; vasoconstriction, bronchodilation
Epinephrine infusion (if refractory)	0.1-1 mcg/kg/min	IV continuous	For persistent hypotension and bronchospasm
Normal saline bolus	10-20 mL/kg	IV over 10-15 minutes	Volume expansion for distributive shock
Hydrocortisone	1-2 mg/kg	IV	Prevent biphasic reaction; anti-inflammatory
Diphenhydramine	1 mg/kg	IV over 5 minutes	H1 antihistamine; adjunctive (NOT first-line)
Ranitidine	1 mg/kg	IV over 5 minutes	H2 antihistamine; adjunctive
Salbutamol nebulization	2.5 mg nebulized	Nebulized	For persistent bronchospasm

Epinephrine: The Cornerstone of Anaphylaxis Treatment

Epinephrine is the only first-line drug for anaphylaxis. No other medication should be given before epinephrine. It works through multiple mechanisms:

• Alpha-1: Vasoconstriction to reverse hypotension and reduce mucosal edema
• Beta-1: Positive inotropy and chronotropy to support cardiac output
• Beta-2: Bronchodilation to reverse bronchospasm; inhibits further mast cell mediator release

Neonatal Epinephrine Dosing for Anaphylaxis

Weight (kg)	IM Dose (mL of 1:10,000)	IV Dose (mL of 1:10,000)
1.0	0.1 mL	0.1 mL (over 1 minute)
1.5	0.15 mL	0.15 mL
2.0	0.2 mL	0.2 mL
2.5	0.25 mL	0.25 mL
3.0	0.3 mL	0.3 mL
3.5	0.35 mL	0.35 mL
4.0	0.4 mL	0.4 mL

Vancomycin Red Man Syndrome: The Most Common NICU Drug Reaction

Red Man Syndrome (RMS) is the most frequently encountered adverse drug reaction in the NICU. It is an anaphylactoid (non-IgE) reaction caused by direct histamine release from mast cells during vancomycin infusion.

Clinical Features

• Erythematous flushing of the face, neck, and upper trunk (the classic "red man" distribution)
• Hypotension (can be severe)
• Tachycardia
• Pruritus
• Usually occurs during or immediately after vancomycin infusion

Prevention and Management

Strategy	Details
Prevention	Infuse vancomycin over at least 60 minutes (longer for higher doses); many NICUs use 90-120 minute infusions
Pre-medication	Diphenhydramine 1 mg/kg IV 30 minutes before vancomycin in patients with prior RMS
Acute management	Stop infusion; give diphenhydramine 1 mg/kg IV; fluid bolus for hypotension; resume at slower rate once resolved
Rechallenge	RMS does not preclude future vancomycin use; slow the infusion rate further and pre-medicate

Blood Product Transfusion Reactions

Transfusion reactions are among the most common severe adverse reactions in the NICU. Types relevant to neonates include:

Acute Hemolytic Transfusion Reaction

• Cause: ABO incompatibility (most common), other antibody-mediated hemolysis
• Signs: Fever, hemoglobinuria (dark urine), jaundice, hypotension, DIC
• Management: Stop transfusion immediately, NS bolus, maintain urine output with furosemide, monitor for DIC, send blood bank samples

Allergic Transfusion Reaction

• Cause: Reaction to plasma proteins in donor blood
• Signs: Urticaria, flushing, rarely anaphylaxis
• Management: Stop transfusion, diphenhydramine, epinephrine if anaphylaxis, use washed blood products for future transfusions

TRALI (Transfusion-Related Acute Lung Injury)

• Cause: Donor anti-leukocyte antibodies activating recipient neutrophils in pulmonary vasculature
• Signs: Acute respiratory distress within 6 hours of transfusion, bilateral pulmonary infiltrates, non-cardiogenic pulmonary edema
• Management: Supportive respiratory care, supplemental oxygen or mechanical ventilation; diuretics are NOT helpful (non-cardiogenic edema); typically resolves in 48-72 hours

Drug-Induced Skin Reactions in Neonates

Severe cutaneous drug reactions, while rare in neonates, include:

• Stevens-Johnson Syndrome (SJS): Less than 10% body surface area epidermal detachment; caused by phenobarbital, phenytoin, antibiotics; manage with immediate drug withdrawal, supportive skin care, fluid and electrolyte management, pain control
• Toxic Epidermal Necrolysis (TEN): Greater than 30% BSA involvement; life-threatening; requires burn-unit level care, dermatology and ophthalmology consultation
• Drug-induced DRESS syndrome: Drug Reaction with Eosinophilia and Systemic Symptoms; fever, rash, eosinophilia, organ involvement; typically 2-8 weeks after drug initiation

Monitoring After Anaphylaxis

All neonates who experience anaphylaxis or severe drug reactions require extended monitoring:

• Continuous cardiorespiratory monitoring for minimum 24 hours (biphasic reactions can occur 4-12 hours after initial episode)
• Document the reaction in the medical record with specific drug, timing, symptoms, and treatment
• Apply allergy alert to the medical chart and drug administration system
• Report to the hospital adverse drug reaction committee and pharmacovigilance system
• Tryptase level (if available) drawn 1-2 hours after the reaction to confirm mast cell activation
• Consider allergy testing referral at 6-12 months of age for confirmed IgE-mediated reactions

Prevention of Drug Reactions in the NICU

• Always check for documented allergies before administering any medication
• Infuse vancomycin, amphotericin, and blood products at recommended rates; never rush infusions
• Ensure cross-matching and blood type verification before every transfusion
• Have emergency medications (epinephrine, diphenhydramine, NS) immediately available at every bedside during first doses of new antibiotics and during transfusions
• Use latex-free equipment for all neonatal care
• HEAMAC neonatal care resources support Indian NICUs in maintaining drug safety protocols, adverse reaction reporting systems, and emergency anaphylaxis management kits at every NICU bedside

Indian NICU Considerations

Drug reaction management in Indian NICUs requires awareness of several context-specific factors:

• Pharmacovigilance reporting to CDSCO (Central Drugs Standard Control Organization) is encouraged for all serious adverse drug reactions in neonates
• Generic drug formulations common in India may have different excipients that can trigger reactions; document brand-specific reactions
• Latex allergy prevention is important; many Indian NICUs are transitioning to latex-free gloves and equipment
• Blood product safety: ensure blood bank follows ABO and Rh typing, crossmatch, and infectious disease screening per NACO guidelines
• Emergency epinephrine should be available in pre-drawn syringes at every NICU bedside

Conclusion

While anaphylaxis and severe drug reactions are uncommon in neonates, their potential for rapid cardiovascular collapse demands that every NICU team be prepared with a clear emergency protocol. Epinephrine is the only first-line treatment and must never be delayed in favor of antihistamines or corticosteroids. Prevention through careful drug administration practices, appropriate infusion rates, blood product safety protocols, and allergy documentation is equally important. Indian NICUs should incorporate drug reaction emergency management into regular simulation training to ensure rapid, effective response when these rare but life-threatening events occur.